Furcation Defects
Conditions
Brief summary
The aim of the study is to evaluate and compare the effectiveness of extended platelet-rich fibrin (ePRF) alone and in combination with bioactive glass nanoparticles in the treatment of grade II furcation defects clinically and radiographically.
Detailed description
A total of 30 grade II furcation defects will be randomly divided into three groups as follows: Group I: 10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone. Group II: 10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF). Group III: 10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane.
Interventions
PROCEDUREGroup I (extended platelet-rich fibrin)
mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group
PROCEDUREGroup II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)
bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF)
PROCEDUREGroup III (bioactive glass nanoparticles and covered by a collagen membrane)
bioactive glass nanoparticles and covered by a collagen membrane
Sponsors
Merna Nasser Mohamed Mostafa Ibrahim Elnahas
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Presence of Glickman's grade II furcation defects in molars probing depth (PD) ≥5 mm horizontal PD ≥3 mm. * The patients are in good systemic health and had not undergone any periodontal surgery in the areas to be treated within the prior 12 months.
Exclusion criteria
* Smokers and tobacco chewers. * Patients that take any medications within the past 6 months that could alter their periodontal status. * pregnant or lactating females. * Patients with known allergy to materials or drugs that will be used or prescribed in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be the amount of bone fill vertically and horizontally obtained in the treatment of grade II furcation defects calculated from CBCT data in millimeters | 6 months follow up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the secondary outcomes include improvements (decrease)of probing depth in millimetres | 3 and 6 months follow up | Using UNC-15 periodontal probe to measure the probing depth from the base of the pocket to the free gingival margin. All measurements will be rounded off to the nearest millimetre. |
| the secondary outcomes include improvements (decrease)of clinical attachment level loss in millimetres | 3 and 6 months follow up | using a UNC-15 periodontal probe to measure clinical attachment level loss from the cemento-enamel junction (CEJ) to the pocket depth. All measurements will be rounded off to the nearest millimetre |
| the secondary outcomes include improvements (decrease) of gingival recession measured in millimetres | 3 and 6 months follow up | Using a UNC-15 periodontal probe to measure gingival recession from cemento-enamel junction (CEJ) to the free gingival margin. All measurements will be rounded off to the nearest millimetre |
| the secondary outcomes include improvements (decrease) of gingival bleeding index | 3 and 6 months follow up | It's performed through gentle probing of the orifice of the gingival crevice using a UNC-15 periodontal probe. If bleeding occurs within 10 seconds a positive finding is recorded, and the number of positive sites is recorded and then expressed as a percentage of the number of the sites examined. |
Countries
Egypt
Outcome results
None listed